Weekly Replacement Soft Contact Lenses for Astigmatism
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but if you are using any medications that might affect the study, the investigator may ask you to stop.
What data supports the effectiveness of the treatment One week replacement soft contact lenses for astigmatism?
Are weekly replacement soft contact lenses for astigmatism safe for humans?
How do weekly replacement soft contact lenses for astigmatism differ from other treatments?
Weekly replacement soft contact lenses for astigmatism are unique because they are designed to be replaced every week, which can help reduce complications from lens contamination compared to lenses that are replaced less frequently. This frequent replacement schedule may offer better comfort and eye health for people with astigmatism.12111213
What is the purpose of this trial?
This open-label study is of adults with astigmatism who have never worn contact lenses. Subjects will be fit into a one week planned-replacement contact lenses and will wear lenses for approximately 3 weeks. Subjects will return for vision and lens fit assessments and will complete surveys about their wear experience.
Eligibility Criteria
This trial is for adults with astigmatism who have never worn contact lenses before. Participants will be asked to wear new soft contact lenses that are replaced weekly and must attend follow-up visits.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are fit with one week planned-replacement soft contact lenses and wear them for approximately 3 weeks
Follow-up
Participants are monitored for vision and lens fit assessments and complete surveys about their wear experience
Treatment Details
Interventions
- One week replacement soft contact lenses
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ohio State University
Lead Sponsor
Alcon Research
Industry Sponsor
Raquel C. Bono
Alcon Research
Chief Medical Officer since 2022
MD from Harvard Medical School
David Endicott
Alcon Research
Chief Executive Officer since 2018
MBA from University of Southern California